Press Releases Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
8.37 ^USD	-5.74%		-13.71%	+2.95%

Jun. 01	Transcript : Iovance Biotherapeutics, Inc. - Special Call
May. 13	Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iovance Biotherapeutics : Corporate Presentation	May. 31	PU
Iovance Biotherapeutics : IOV COM 202 Cohort 1A ASCO 2024 Oral Presentation	May. 31	PU
Iovance Biotherapeutics to Present at Upcoming Conferences and Events	May. 24	AQ
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting	May. 23	AQ
Iovance Biotherapeutics : 2022 Annual Report	May. 22	PU
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	May. 20	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	May. 17	AQ
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	May. 14	AQ
Iovance Biotherapeutics: Q1 Earnings Snapshot	May. 09	AQ
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates	May. 09	AQ
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024	May. 01	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	Apr. 30	AQ
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting	Apr. 24	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024	Apr. 22	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	Apr. 19	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	Mar. 25	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	Mar. 22	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	Mar. 04	AQ
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	Mar. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Press Releases

Filters